Long-term treatment with the oral direct thrombin inhibitor ximelagatran, compared to warfarin, as stroke prophylaxis in patients with atrial fibrillation. A long term follow-up study

Trial Profile

Long-term treatment with the oral direct thrombin inhibitor ximelagatran, compared to warfarin, as stroke prophylaxis in patients with atrial fibrillation. A long term follow-up study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2010

At a glance

  • Drugs Warfarin; Ximelagatran
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top